Arcturus Therapeutics (ARCT) Tops Q4 EPS by 25c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q4 EPS of ($1.47), $0.25 better than the analyst estimate of ($1.72). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $14.72 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Goldman Sachs Downgrades Bank Mandiri (BMRI:IJ) (PPERF) to Sell, 'Liquidity and capital tightness'
• Oppenheimer Starts Teva Pharma (TEVA) at Outperform